Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on holding the 2024 semi-annual results briefing
Hainan Huluwa Pharmaceutical Group Co., Ltd. Investor Relations Activity Record Form
Announcement of Resolutions of the Fourth Meeting of the Third Board of Supervisors of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the Fourth Meeting of the Third Board of Directors of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Special report on the storage and actual use of funds raised in the 2024 semi-annual period of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on obtaining a drug registration certificate for inhaled acetylcysteine solution
Hainan Huluwa Pharmaceutical Group Co., Ltd. Investor Relations Activity Record Form
Announcement on obtaining the approval notice for drug clinical trials by Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on Obtaining the Registration Certificate of Propofol and Tenofovir Disoproxil Fumarate Tablets.
Announcement from Hainan Huluwa Pharmaceutical Group Co., Ltd. regarding the generic drug consistency evaluation of omeprazole enteric-coated capsules.
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. Obtaining the Registration Certificate for Montelukast Sodium Chewable Tablets
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. receiving notification of pharmaceutical GMP compliance inspection report.
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. receiving government subsidies
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. receiving government subsidies
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on holding a performance briefing for the first quarter of 2023 and 2024
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on participating in the “2023 Hainan Listed Companies Performance Briefing Conference and Investor Group Reception Day”
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on obtaining a drug registration certificate
Ernst & Young Huaming (2024) reviews Audit Report No. 70060529_X01
Hainan Huluwa Pharmaceutical Group Co., Ltd. 2023 Independent Director Debriefing Report (Liu Qiuyun)
Hainan Huluwa Pharmaceutical Group Co., Ltd. 2023 Environmental, Social and Corporate Governance (ESG) Report
No Data
No Data